Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Zacks Investment Research9/23/2026Neutral
IDXX
IDEXX Laboratories IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$40.91B
P/E Ratio
37.04
EPS
$14.02
Beta
1.54
52W High
$769.98
52W Low
$500.61
50-Day MA
$547.88
200-Day MA
$593.35
Dividend Yield
—
Profit Margin
25.00%
Forward P/E
31.45
PEG Ratio
2.85
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Fundamentals
| Revenue (TTM) | $4.55B |
| Gross Profit (TTM) | $2.84B |
| EBITDA | $1.62B |
| Operating Margin | 35.00% |
| Return on Equity | 74.20% |
| Return on Assets | 27.10% |
| Revenue/Share (TTM) | $57.17 |
| Book Value | $20.45 |
| Price-to-Book | 25.48 |
| Price-to-Sales (TTM) | 9.00 |
| EV/Revenue | 9.22 |
| EV/EBITDA | 25.98 |
| Quarterly Earnings Growth (YoY) | 17.60% |
| Quarterly Revenue Growth (YoY) | 9.70% |
| Shares Outstanding | $78.78M |
| Float | $78.50M |
| % Insiders | 0.22% |
| % Institutions | 96.72% |
Historical Volatility
HV 10-Day
16.30%
HV 20-Day
21.53%
HV 30-Day
23.83%
HV 60-Day
28.00%
HV Rank
15.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($698.92 target)
4
Strong Buy4
Buy5
Hold1
Strong SellLatest News
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
MarketBeat9/20/2026Positive
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
Zacks Investment Research9/17/2026Positive
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
Business Wire9/17/2026Neutral
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/3/2026Negative
Baron Focused Growth Fund Q2 2026 Portfolio Update
Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.
Seeking Alpha9/3/2026Positive
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.
Business Wire8/31/2026Neutral
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/31/2026Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/24/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IDXX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026